NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Celldex Therapeutics, Inc. (CLDX) Stock Analysis

Celldex Therapeutics, Inc. (CLDX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CLDX

$29.37

−$0.92 (−3.04%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CLDX with… →

CLDX Key Statistics

As of Oct 21, 2026
Trading
Open
$30.29
Previous Close
$30.29
Day's Range
29.31–30.72
52-Week Range
22.10–45.14
Volume
1.12M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.90
Valuation
Market Cap
$2.22B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.35
Financials (FY)
Revenue (FY)
$1.55M−77.99%
Net Income (FY)
−$258.76M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
78.53M
1-Year Return
+5.23%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
1.33M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CLDX closed at $29.37, +5.23% over 1 year.

Celldex Therapeutics, Inc. (CLDX) has a market capitalization of $2.22B.

In fiscal 2025, CLDX reported revenue of $1.55M.

CLDX Stock Return by Calendar Year

Celldex Therapeutics, Inc. (CLDX) 10-year return: what $10,000 became

1 year
$10,000 $10,523
+5.23%
5 years
$10,000 $6,316
−36.84%
10 years
$10,000 $5,862
−41.38%

If you had invested $10,000 in Celldex Therapeutics, Inc. (CLDX) 10 years ago, at the close on October 21, 2016, it would have been worth $5,862 at the close on October 21, 2026: −41.38% in total, −5.20% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+8.14%
2025+7.48%
2024−36.28%
2023−11.02%
2022+15.35%
2021+120.55%
2020+685.65%
2019−25.67%
2018−92.96%
2017−19.77%
2016 (partial year)−21.68%

As of October 21, 2026.

CLDX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.55M−$258.76M−16,748.0%
2024$7.02M−$157.86M−2,248.8%
2023$6.88M−$141.43M−2,054.8%
2022$2.36M−$112.33M−4,765.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.55M—−$287.37M−$258.76M−16,748.0%
2024$7.02M—−$195.08M−$157.86M−2,248.8%
2023$6.88M—−$142.04M−$141.43M−2,054.8%
2022$2.36M—−$107.10M−$112.33M−4,765.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Celldex Therapeutics, Inc. (CLDX) is capitalised at $2.22B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 198.

The 52-week range on file runs from $22.10 to $45.14. CLDX last closed at $29.37 on October 21, 2026. That is −$0.92 (−3.04%) against the previous close. The latest close sits 32.9% above that 52-week low.

Financial Health

In fiscal 2025, Celldex Therapeutics, Inc. reported revenue of $1.55M. That is −77.99% against the prior fiscal year, when revenue was $7.02M. The same year closed with a net loss of $258.76M. Trailing earnings per share are −4.35.

Across the 4 fiscal years on file, revenue moves from $2.36M in 2022 to $1.55M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is +5.23%. Across 10 years the annualized return works out at −5.20%. The reported beta is 0.9. Daily returns over the trailing 10 years annualize to a volatility of 77.81%.

Growth & Income

The record shows no dividend for CLDX.

So far in 2026 the total return is +8.14%. Across the complete calendar years on file, 2020 returned +685.65% and 2018 returned −92.96%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Celldex Therapeutics, Inc. (CLDX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Celldex Therapeutics, Inc. CLDX $2.22B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Celldex Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Visit website →